Also known as: cannabinol · the sleepy cannabinoid · aged-THC byproduct

CBN and Sleep

What the evidence actually says about cannabinol as a sleep aid, separating lab data from marketing claims.

Sourced and fact-checked
8 cited sources
Published 3 months ago
How this page was made
↯ The honest take

CBN is marketed as 'the sleep cannabinoid,' but that reputation rests on a 1970s misunderstanding and a lot of gummy advertising. The actual human data is thin: one small recent trial showed a modest improvement in sleep disturbance, and that's about it. CBN is not strongly sedating on its own at consumer doses. If a CBN product helps you sleep, it's likely the THC contamination, the ritual, or placebo doing most of the work. Real, but small. Not magic.

Not Medical Advice

This article is not medical advice. It summarizes published research and labels each claim by evidence quality. Sleep problems can be symptoms of underlying conditions (sleep apnea, depression, thyroid disease, medication interactions) that need real diagnosis. If you have chronic insomnia, talk to a clinician before self-treating with any cannabinoid product. Drug interactions with CBN are poorly studied — assume caution if you take other sedatives, benzodiazepines, opioids, or CYP450-metabolized medications.

Plain-Language Summary

CBN (cannabinol) is what THC slowly turns into when cannabis is exposed to oxygen, heat, and light over time. Old, badly stored weed has more CBN than fresh weed. Around the 1970s, researchers noticed that aged cannabis seemed more sedating, and CBN got blamed for it. Later work showed the sedation was probably from other degradation products and residual THC, not CBN itself [1][2] Disputed.

Despite this, CBN became the centerpiece of a sleep-gummy industry. The honest current picture: there is one small, placebo-controlled human trial showing CBN modestly reduced sleep disturbance, and a handful of preclinical and observational studies. That's it. The evidence is real but weak, and the marketing wildly outruns it.

What Probably Works

Honestly? Nothing about CBN for sleep is at the 'probably works' tier yet. No claim about CBN as a sleep aid has the replicated, adequately-powered human trial data needed to call it well-established No data.

For context, treatments that do sit at this tier for insomnia include cognitive behavioral therapy for insomnia (CBT-I) and certain prescription medications [3]. CBN is not in that category, and any product label suggesting otherwise is overselling.

What Might Work

Reducing subjective sleep disturbance at 20 mg nightly. A 2023 randomized, double-blind, placebo-controlled trial by Bonn-Miller and colleagues gave healthy adults with sleep complaints 20 mg of CBN nightly for one week. The CBN group reported a small but statistically significant reduction on the PROMIS Sleep Disturbance scale versus placebo. Nighttime awakenings also decreased modestly. There was no significant effect on sleep onset latency or total sleep time [4] Weak / limited.

This is the strongest direct human evidence that exists. It's one trial, one week, one dose, in healthy volunteers — not insomnia patients. It is suggestive, not conclusive.

CBN + THC combinations. Some clinicians and users report that CBN feels more sedating when combined with low-dose THC. There is limited preclinical work suggesting additive effects, but no controlled human sleep trial has cleanly isolated this combination Anecdote. Most commercial 'CBN sleep' products also contain THC or melatonin, which makes it impossible for consumers to tell which ingredient is doing the work.

What Doesn't Work, or Has Weak Evidence

'CBN is 5x more sedating than diazepam.' This claim circulates widely in cannabis marketing and is not supported by any published comparative trial. It appears to be a mutation of unrelated rodent data and should be treated as folklore No data.

Low-dose CBN (2.5–5 mg) gummies as a sleep aid. Most over-the-counter CBN products dose well below the 20 mg used in the only positive human trial. There is no evidence that 2.5 or 5 mg of isolated CBN produces meaningful sleep effects No data. If these products work for users, residual THC, added melatonin, or placebo are plausible explanations.

CBN as a standalone sedative. Early human studies in the 1970s found that pure CBN did not produce sedation in volunteers; only THC + CBN combinations produced drowsiness, and the effect tracked with THC dose [1][2] Disputed. The 'CBN = sedation' narrative emerged from misreading these results.

What We Don't Know

Comparison with Standard Treatments

CBT-I (cognitive behavioral therapy for insomnia) is the first-line treatment for chronic insomnia per the American College of Physicians and the American Academy of Sleep Medicine [3][6]. It has durable effects, no pharmacology, and outperforms most sleep medications long-term. Nothing about CBN comes close to this evidence base.

Prescription hypnotics (z-drugs like zolpidem, orexin antagonists like suvorexant) have well-characterized efficacy and side-effect profiles. They also have well-documented risks (dependence, next-day impairment, complex sleep behaviors).

Melatonin has modest evidence for sleep-onset issues and circadian disorders, with a strong safety profile [7]. Many 'CBN sleep' products include melatonin, which likely contributes more to their effect than the CBN does.

THC has more evidence than CBN for short-term subjective sleep improvement, but tolerance develops, REM is suppressed, and discontinuation can rebound-worsen sleep [5] Weak / limited.

In a fair ranking for chronic insomnia: CBT-I >> melatonin / prescription hypnotics > THC > CBN.

Risks and Considerations

CBN appears reasonably well-tolerated in the limited human data available. Reported side effects at 20 mg include mild drowsiness the next morning and, rarely, GI discomfort [4]. Specific risks worth knowing:

Sources

  1. Peer-reviewed Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. Effects of Δ9-tetrahydrocannabinol and cannabinol in man. Pharmacology. 1975;13(6):502-512.
  2. Peer-reviewed Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology. 2008;153(2):199-215.
  3. Peer-reviewed Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine. 2016;165(2):125-133.
  4. Peer-reviewed Bonn-Miller MO, Feldner MT, Bynion TM, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology. 2024.
  5. Peer-reviewed Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports. 2017;19(4):23.
  6. Peer-reviewed Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. 2021;17(2):255-262.
  7. Peer-reviewed Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Medicine Reviews. 2017;34:10-22.
  8. Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708-1709.

How this page was made

Generation history

Jan 23, 2026
Fact-check pass — raised 2 flags
Jan 22, 2026
Initial draft

Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.